Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelicapavir for Respiratory Syncytial Virus Infection in Adults Who Are at High Risk for Severe Disease

NCT07908381 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07908381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelicapavir for Respiratory Syncytial Virus Infection in Adults Who Are at High Risk for Severe Disease
Lead sponsor
Enanta Pharmaceuticals, Inc
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 19, 2026
Completion date
July 31, 2029
Enrollment
860 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

rsv

Arms

As registered; 2 arms.

  • zelicapavir Experimentalzelicapavir

    Zelicapavir 800 mg, orally

  • Placebo Placebo comparatorPlacebo

    Matching placebo, orally

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Time to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scale Day 1 through Day 21

Lead sponsor's other trials

Enanta Pharmaceuticals, Inc, most recent start first.

Similar trials

Same condition (Pulmonary Disease, Chronic Obstructive) and phase, most recent start first.